Survival of Thalassemic Patients Referred to the Boo Ali Sina Teaching Hospital, Sari, Iran

REFERENCES

• Borgna-Pignatti C, Rugolotto S, DeStefano P, Piga A, Di Gregorio F, Gamberine MR. Survival and disease complications in thalassemia major. Ann NY Acad Sci 1998; 850: 227–231
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, DeStefano P. Survival and complications in patients with thalassaemia major treated with transfusion and deferoxamine. Haematologica 2004; 89(10)1187–1193
   PubMed Web of Science ®Google Scholar
• Modell B, Letsky EA, Flynn DM, Peto R, Weatherall DJ. Survival and desferrioxamine in thalassaemia major. BMJ 1982; 284(6322)1081–1084
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994; 331(9)574–577
   PubMed Web of Science ®Google Scholar
• Ward A, Caro JJ, Green TC, Huybrechts K, Arana A, Wait S, Eleftheriou A. An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use. BMC Clin Pharmacol 2002; 2: 3
   PubMedGoogle Scholar
• Samavat A, Modell B. Iranian national thalassaemia screening programme. BMJ 2004; 329(7475)1134–1137
   PubMed Web of Science ®Google Scholar
• Pearson HA, Cohen AR, Giardina PJ, Kazazian HH. The changing profile of homozygous β-thalassemia demography and age distribution of current North America patients and changes in two decades. Pediatrics 1996; 97(3)352–356
   PubMed Web of Science ®Google Scholar
• Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK. Data from the UK Thalassaemia Registry. Lancet 2000; 355(9220)2051–2052
   PubMed Web of Science ®Google Scholar
• Rahman M, Lodhi Y. Prospects and future of conservative managment of β thalassaemia major in a developing country. Pak J Med Sci 2004; 20(2)105–112
   Google Scholar
• Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, Di Gregorio F, Burattini MG, Terzoli S. Survival and causes of death in thalassaemia major. Lancet 1989; 2(8653)27–30
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Olivieri NF, McGee A, Liu P, Korea G, Freedman MH, Benson L. Cardiac disease-free survival in patients with thalassemia major treated with subcutaneous desferrioxamine: an update on the Toronto cohort. Ann NY Acad Sci 1990; 612: 585–586
   Google Scholar
• Reshidighader F, Kosaryan M, Farzin D, Afshin R. The effect of high dose intravenous Desferal on cardiac function of thalassemia major patients. J Mazandaran Univ Med Sci 2005; 47(15)6–13
   Google Scholar
• Ghaemian A, Hoseini A, Kosaryan M, Maanavifar R. Left ventricular diastolic abnormalities in β thalassemia major with normal systolic function. Med J Islamic Repub Iran 2002; 16(1)50–58
   Google Scholar
• Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998; 103(2)361–364
   PubMed Web of Science ®Google Scholar
• Kattamis A, Ladis V, Berdousi H, Kelekis NL, Alexopoulou E, Papasotiriou I, Drakaki K, Kaloumenou I, Galani A, Ch Kattamis. Iron chelation treatment with combined therapy with deferiprone and deferoxamine : a 12-month trial. Blood Cells Mol Dis 2006; 36(1)21–25
   PubMed Web of Science ®Google Scholar
• Link G, Konijin AM, Beuer W, Cabantchik ZI, Hershko C. Exploring the “iron shuttle” hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment on hypertransfused rats with labeled iron stores and iron-loaded rat heart cells in culture. J Lab Clin Med 2001; 138(2)130–138
   PubMed Web of Science ®Google Scholar
• Telfer PT, Prescott E, Holden S, Walker M, Hoffbrand AV, Wonke B. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 2000; 110(4)971–977
   PubMed Web of Science ®Google Scholar
• Gamberini MR, Fortini M, gilli G, Testa MR, De Sanctis V. Epidemiology and chelation therapy effects on glucose homeostasis in thalassemia patients. J Pediatr Endocrinol Metab 1998; 11(Suppl 3)867–869
   PubMedGoogle Scholar
• Piga A, Galioti C, Fogliacco E, Tricta F. Comparative effect of deferiprone and deferoxamine on survival and cardiac disease in patient with thalassaemia major: a retrospective analysis. Haematologica 2003; 88(5)489–496
   PubMed Web of Science ®Google Scholar